Chaim Hurvitz, Director at NRX Pharmaceuticals, Inc. (NRXP), bought 70,000 shares at $0.29 ($20K) on 2023-08-30, disclosed to the SEC on 2023-09-11.
Open-market purchase of $20k NRXP by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Clearly above the average filing.